IPO及再融资上会预告 据交易所官网审核动态信息，本周（9月22日-9月26日）IPO上会审核4家企业，全部获通过，合计拟募资122.33亿元。 本周2家再融资企业上会，全部获通过，合计拟募资8.24亿元。 | 上会日期 数量 | 樂型 | 申报板块 | 公司简称 | 注册地 审核结果 | | 拟募资金额 | 最近一年净利润 | 保荐机构 会计师事务所 律师事务所 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | (万元) | (万元) | | | | | 2025-9-25 | 公开发行 可转债 | 创业板 | 普联软件 | 山东 | 通过 | 24,293.26 | 12,362.43 | 中泰证券 | 致同 | 中伦 | | 2025-9-26 | 公开发行 可转债 | 科创板 | 茂莱光学 | 江苏 | 通过 | 58,125.00 | 3,552.10 | 中争公司 | 公证天业 | 锦天城 | | | | | | | HEADING CONSULTING | | | | | ...

证券时报·数据宝统计显示，9月24日，上交所上市审核委员会2025年第38次审议会议结果公告显示，百 奥赛图(北京)医药科技股份有限公司(简称百奥赛图)首发申请获上市委会议通过。 公司基于自主开发的基因编辑技术提供各类创新模式动物以及临床前阶段的医药研发服务。本次发行保 荐机构为中国国际金融股份有限公司。公司拟发行股数9984.96万股，拟募集资金11.85亿元。 研发投入方面，近三年公司研发投入分别为6.99亿元、4.74亿元、3.24亿元，占营业收入比例分别为 130.96%、66.17%、33.04%。截至2024年12月31日，公司共有研发人员337人，占同期公司员工人数的 30.78%。（数据宝） 公司主要财务指标 | 财务指标/时间 | 2024年 | 2023年 | 2022年 | | --- | --- | --- | --- | | 营业收入（万元） | 98045.39 | 71691.18 | 53388.08 | | 归属母公司股东的净利润（万元） | 3354.18 | -38295.03 | -60194.47 | | 扣除非经常损益后归属母公司所有者净利润（万元） | 2296. ...

9月24日，百奥赛图(北京)医药科技股份有限公司（百奥赛图）科创板上市将迎来上会，保荐机构是中 国国际金融证券。 据短平快解读了解，2009年11月，百奥赛图前身百奥赛图有限成立，股东包括杨晓明、沈月雷、倪健、 万里明，持股比例分别为35.16%、28.85%、25.99%、10%；2020年12月完成股份制改革。 实控人表决权不到30%。百奥赛图的控股股东、实际控制人均为沈月雷、倪健，两人系夫妻关系，截至 招股书披露日，直接持股比例分别为6.61%、7.26%。另外，沈月雷是百奥常青、百奥常盛、祐和常 青、祐和常盛股权激励平台的普通合伙人、执行事务合伙人，有权执行合伙事业，控制的表决权约 13.16%。 百奥赛图是一家临床前CRO以及生物技术企业，基于自主开发的基因编辑技术提供各类创新模式动物 以及临床前阶段的医药研发服务，公司称与全球前十大制药企业（以2024年度销售收入计算）均建立了 合作关系。 梳理来看，实控人表决权不到30%，存在大额未偿还借款；募资缩水超7亿，还要融资11.85亿；研发费 用持续下滑，研发人员缩减；因专利侵权被告，被索赔100万元；收入稳增，摆脱亏损；资产负债率高 于同行，达到65 ...

Summary of Key Points Core Viewpoint - This week, one new stock will be available for subscription, while four companies are undergoing IPO reviews, indicating ongoing activity in the capital markets [2][3]. Group 1: New Stock Subscription - One new stock, Aomeisen, will be available for subscription on Monday, September 25 [2]. - Last week, Shichang Co. debuted on the North Exchange, experiencing a significant first-day increase of 271.56% [2]. Group 2: Company Performance and Financials - Shichang Co. specializes in the research, production, and sales of automotive fuel systems, primarily selling to major vehicle manufacturers like Geely and FAW [2]. - Baiaosaitu, known as the "first stock in gene editing," plans to raise approximately 11.85 billion yuan for early drug development services and other projects [3][5]. - Baiaosaitu's projected revenues for 2022, 2023, and 2024 are 534 million yuan, 717 million yuan, and 980 million yuan, respectively, with net profits expected to improve from a loss of 602 million yuan in 2022 to a profit of 33.54 million yuan in 2024 [3][4]. Group 3: Fundraising and Investment Plans - The fundraising plan for Baiaosaitu includes allocations of 45.36 million yuan for early drug development services, 31.65 million yuan for antibody drug research, and 16.5 million yuan for preclinical research [6]. - The total investment amount for these projects is 118.5 million yuan, with the majority directed towards early drug development services [6].

Summary of Key Points Core Viewpoint - Four companies are set to present their IPO applications at the upcoming listing committee meetings of the Shenzhen Stock Exchange, Shanghai Stock Exchange, and Beijing Stock Exchange, indicating a robust pipeline of new listings in the market [1]. Group 1: Upcoming IPOs - Yuan Chuang Co., Ltd. plans to list on the Shenzhen Main Board, focusing on the research, production, and sales of rubber track products [3]. - Xin Guang Yi intends to list on the ChiNext Board, specializing in high-performance special functional materials, including anti-adhesion special films and strong resistance special films [4]. - You Xun Co., Ltd. and Bai Ao Sai Tu are both targeting the Sci-Tech Innovation Board (STAR Market) for their IPOs, with You Xun focusing on optical communication front-end transceiver chips and Bai Ao Sai Tu providing innovative model animals and preclinical pharmaceutical research services based on self-developed gene editing technology [5]. Group 2: Fundraising Details - Bai Ao Sai Tu is expected to raise the highest amount of 1.185 billion yuan, with funds allocated for early drug research service platform construction, working capital, and various R&D projects [1]. - You Xun plans to raise 808 million yuan, while Xin Guang Yi aims for 638 million yuan in their respective fundraising efforts [1]. - The geographical distribution of the upcoming IPOs includes one company each from Beijing, Fujian, Jiangsu, and Zhejiang provinces [1]. Group 3: Underwriting Institutions - You Xun and Xin Guang Yi are both backed by CITIC Securities as their underwriting institution [2]. - Bai Ao Sai Tu is sponsored by China International Capital Corporation (CICC), while Yuan Chuang is underwritten by Guotai Junan Securities [5].

Group 1 - The stock price of Bid Pharma closed at 58.79 yuan on August 6, 2025, down by 1.78 yuan, representing a decline of 2.94% from the previous trading day [1] - The opening price on the same day was 61.50 yuan, with a highest price of 61.95 yuan and a lowest price of 58.60 yuan, with a trading volume of 14,360 lots and a transaction amount of 86 million yuan [1] - Bid Pharma operates in the biopharmaceutical industry, focusing on pharmaceutical research and development services, and is recognized as a specialized and innovative enterprise in the Shanghai market, also involved in the CRO business [1] Group 2 - On August 6, the net outflow of main funds was 5.3635 million yuan, accounting for 0.21% of the circulating market value [1] - Over the past five trading days, the cumulative net outflow reached 11.2451 million yuan, representing 0.44% of the circulating market value [1]

Group 1 - The core stock price of Bid Pharma on July 30 was 59.06 yuan, down by 2.42 yuan, representing a decline of 3.94% [1] - The trading volume on the same day was 100 million yuan, with a turnover rate of 3.84%, and the total market capitalization stood at 5.368 billion yuan [1] - Bid Pharma specializes in the biopharmaceutical sector, focusing on pharmaceutical research and development services, and operates within the bioproducts and CRO industry segments [1] Group 2 - The company will hold its fourth extraordinary general meeting of shareholders for 2025 on July 31 to discuss multiple proposals, including changes to its business scope, the cancellation of the supervisory board, and amendments to the company’s articles of association [1] - The meeting will take place at the conference room on the 6th floor of Building 3, No. 999 Xiangyin Road, Yangpu District, Shanghai [1] - On July 30, the net outflow of main funds was 15.3766 million yuan, accounting for 0.6% of the circulating market value [1]

Group 1 - The company announced a delay in the completion dates for two fundraising investment projects, moving the expected operational status from June 2025 to June 2026 [1] - The projects affected are the "Pharmaceutical Liquid Preparation System Production Center Construction Project" and the "Pharmaceutical R&D Service Platform Upgrade and Expansion Project" [1] - The delay does not change the investment content, total amount, or implementing entity, and is not expected to have a substantial impact on project implementation or the company's normal operations [1] Group 2 - As of May 31, 2025, the company has cumulatively invested 164 million yuan in the fundraising projects, with a remaining balance of 109 million yuan in the fundraising account [1]

Core Viewpoint - The recent surge in mergers and acquisitions (M&A) in the A-share market reflects a deep-seated logic of industrial upgrading and strategic transformation, showcasing the diversification and specialization of the current M&A landscape [1] Group 1: Characteristics of Recent M&A Activity - Cash transactions dominate the current wave of M&A, with companies accelerating their entry into new sectors [2] - The M&A activities are driven by three strategic directions: seeking breakthroughs in technological innovation, enhancing risk resilience through resource integration, and capitalizing on policy incentives to enter emerging sectors like AI and semiconductors [2] Group 2: Industry Chain Integration - Industry chain integration is a core driver of M&A among A-share companies, with firms pursuing horizontal and vertical integration to enhance competitiveness [3] - Jiangsu Zongyi Co., Ltd. plans to acquire control of Jiangsu Jilai Microelectronics Co., Ltd. to extend its reach into the power semiconductor sector [3] - Suzhou Dongshan Precision Manufacturing Co., Ltd. intends to acquire 100% of Groupe Mécanique Découpage to optimize its debt structure and enhance its capabilities in the automotive parts sector [3][4] Group 3: Strategic Focus and Diversification - Companies are adopting divergent strategies, with some focusing on core businesses while others pursue diversification [5] - Jiangsu Zongyi's acquisition of Jilai Microelectronics aims to strengthen its position in the integrated circuit sector, enhancing its technical capabilities and market share [5] - China National Pharmaceutical Group plans to acquire Beijing Jinsui Technology to enter the e-commerce service sector, diversifying its business and revenue streams [5] Group 4: Investment Trends - Beijing Lier High-Temperature Materials Co., Ltd. is investing in Shanghai Zhenliang Intelligent Technology Co., Ltd. to enter the AI chip market, reflecting a commitment to both core business and new growth areas [6] Group 5: Valuation and Compliance Concerns - Valuation and compliance are critical issues in M&A transactions, directly impacting their success [8] - Huafeng Chemical Co., Ltd. terminated its planned acquisition of Zhejiang Huafeng Synthetic Resin Co., Ltd. due to high valuation and lack of shareholder approval, highlighting the risks associated with high-premium related transactions [8][9] - Companies are advised to establish a scientific valuation system and ensure transparency in operations to mitigate risks associated with related-party transactions [10]

安徽万邦医药科技股份有限公司 首次公开发行股票并在创业板上市发行公告 保荐人（主承销商）： 特别提示 安徽万邦医药科技股份有限公司（以下简称"万邦医药"、"发行人"或"公司"）根 据中国证券监督管理委员会（以下简称"中国证监会"）《证券发行与承销管理办法》 （证监会令[第 208 号]）（以下简称"《管理办法》"）、《首次公开发行股票注册管 理办法》（证监会令[第 205 号]）、深圳证券交易所（以下简称"深交所"）《深圳证 券交易所首次公开发行证券发行与承销业务实施细则》（深证上[2023]100 号）（以 下简称"《实施细则》"）、《深圳市场首次公开发行股票网上发行实施细则》（深 证上〔2018〕279 号）（以下简称"《网上发行实施细则》"）、《深圳市场首次公开 发行股票网下发行实施细则（2023 年修订）》（深证上〔2023〕110 号）（以下简 称"《网下发行实施细则》"）、《深圳证券交易所创业板投资者适当性管理实施办 法（2020 年修订》（以下简称"《投资者适当性管理办法》"）和中国证券业协会 （以下简称"证券业协会"）《首次公开发行证券承销业务规则》（中证协发〔2023〕 18 号）、《首次公 ...